

B2
4. (amended) The recombinant influenza virus of Claim 1, 20, 21, 22, 23, 24 or 25 in which the region [of] encoding the tumor-associated antigen is in a bicistronic arrangement with an influenza virus gene.

5. (amended) The recombinant influenza virus of claim 1, 20, 21, 22, 23, 24 or 25 which is attenuated.

Add new Claims 20-29, as follows:

B3
--20. (new) The recombinant influenza virus of Claim 1 wherein the tumor-associated antigen is a human tumor antigen recognized by T lymphocytes.

OK (initials)
21. (new) The recombinant influenza virus of Claim 20 wherein the human tumor antigen is a melanocyte tumor antigen.

22. (new) The recombinant influenza virus of Claim 20 wherein the human tumor antigen is a breast, ovarian, cervical or pancreatic carcinoma antigen.

Excluded
23. (new) The recombinant influenza virus of Claim 20 wherein the human tumor antigen is MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, N-acetylglucosaminyltransferase, or p15.

24. (new) The recombinant influenza virus of Claim 20 wherein the human tumor antigen is beta-catenin, MUM-1, or CDK4.

25. (new) The recombinant influenza virus of Claim 20 wherein the human tumor antigen is HER-2/neu, human papillomavirus-E6, human papillomavirus-E7, or MUC-1.

26. (new) An immunogenic formulation comprising an effective amount of the recombinant influenza virus of Claim 4 and a pharmaceutically acceptable carrier.

27. (new) An immunogenic formulation comprising an effective amount of the recombinant influenza virus of Claim 5 and a pharmaceutically acceptable carrier.